AGTC Announces Financial Results for the Second Quarter

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
AGTC Announces Financial Results for the Second Quarter Ended December 31, 2014

GAINESVILLE, Fla., Feb. 11, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC ), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced financial results for the second quarter ended December 31, 2014.

"We are rapidly advancing our lead programs – X-linked retinoschisis (XLRS) and achromatopsia (ACHM) – toward Phase I/II clinical trials and expect to see initial clinical results for both programs during the second half of 2015," said Sue Washer, President and CEO. "We are also advancing preclinical studies for our product candidate addressing X-linked retinitis pigmentosa (XLRP). There is a significant unmet need for new treatments in these rare genetic eye diseases and we are dedicated to helping these patients achieve better vision. In the longer term, we have begun target analysis in animal models to identify new treatments for age-related macular degeneration (AMD) and we will continue to seek opportunities to take advantage of the adaptability of our gene therapy platform to address a range of genetic diseases, both within and beyond our initial focus area of orphan ophthalmology."  

Select Financial Results for the Second Quarter Ended December 31, 2014

Total revenue for the three months ended December 31, 2014 increased by $137,000 to $652,000 compared to the same period in 2013. The increase was primarily driven by higher grant revenue resulting from increased activity in grant-funded projects, partially offset by a reduction to zero of the company's sponsored research revenue due to the fact that no milestones associated with the sponsored research arrangements were attained during the quarter.   

Research and development expense for the three months ended December 31, 2014 increased by $1.2 million to $3.4 million compared to the same period in 2013. The increase was primarily the result of increased activity relating to the company's XLRS, ACHM, XLRP and other product candidates, including higher facilities and other costs associated with laboratory expansions. In addition, employee-related costs increased during the more recent period primarily as a result of higher expenses associated with share-based compensation plans and the hiring of additional employees.      

General and administrative expense for the three months ended December 31, 2014 increased by $726,000 to $1.9 million compared to the same period in 2013. The increase was primarily the result of higher employee-related costs associated with the company's share-based compensation plans and the hiring of additional employees. In addition, legal, accounting and other administrative expenses have increased due to the additional costs associated with operating as a publicly-traded company.   

The company reported a net loss of $4.65 million in the three months ended December 31, 2014 compared with $735,000 for the same period in 2013.  The lower net loss in 2013 includes favorable fair value adjustments associated with the company's former Series B purchase rights and warrant liabilities which resulted in the recognition of $2.2 million of other income. The purchase rights and warrants were extinguished in connection with the closing of the company's initial public offering in April 2014.

At December 31, 2014, the company's cash, cash equivalents and investments amounted to $96.8 million.

About AGTC

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases in ophthalmology.  AGTC's lead product candidates focus on X-linked retinoschisis, achromatopsia and X-linked retinitis pigmentosa, which are inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments.  AGTC is also pursuing pre-clinical development of treatments for wet AMD using the company's experience in ophthalmology to expand into disease indications with larger markets.

About X-linked Retinoschisis (XLRS)                                                                                         

XLRS is an inherited retinal disease caused by mutations in the RS1 gene, which encodes the retinoschisin protein. It is characterized by abnormal splitting of the layers of the retina, resulting in poor visual acuity in young boys, which can progress to legal blindness in adult men.

About Achromatopsia (ACHM)

ACHM is an inherited retinal disease, which is present from birth and is characterized by the lack of cone photoreceptor function. The condition results in markedly reduced visual acuity light sensitivity causing day blindness, and complete loss of color discrimination. Best-corrected visual acuity in persons affected by ACHM, even under subdued light conditions, is usually about 20/200, a level at which people are considered legally blind.

About X-linked Retinitis Pigmentosa (XLRP)

XLRP is an inherited condition that causes boys to develop night blindness by the time they are ten and progresses to legal blindness by their early forties.

About Age-related Macular Degeneration (AMD)

AMD is a retinal disease that usually affects older adults and results in a loss of vision in the center of the visual field (the macula).  It is a major cause of blindness and visual impairment in older adults and occurs in "dry" and neovascular, or "wet," forms.

Forward Looking Statements

Certain statements in this press release may constitute "forward-looking statements." Such statements relate to a variety of matters, including but not limited to: the anticipated timing of clinical trials for the company's ACHM and XLRS product candidates and the company's expectations regarding its ability to execute its clinical and business strategies. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of the company and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and the company undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise, except as required by law.

Factors that could cause actual results to differ materially from the forward-looking statements contained herein include, but are not limited to the following: our ability to generate revenue from product sales is highly uncertain and we may never achieve or sustain profitability; we will need to raise additional funding in the future, which may not be available on acceptable terms, or at all; clinical drug development is expensive, time consuming and uncertain; no gene therapy products have been approved in the United States and we cannot predict when or if we will obtain regulatory approval to commercialize a product candidate; we rely on third parties to conduct and supervise our clinical trials and to conduct certain aspects of our product manufacturing and protocol development; increased regulatory scrutiny of gene therapy and genetic research could damage public perception of our product candidates or adversely affect our ability to conduct our business; we face substantial competition; and if we are unable to obtain and maintain adequate patent protection for our technology and products, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products could be impaired. Additional factors that could cause actual results to differ materially from those described in the forward-looking statements are set forth under the heading "Item 1A—Risk Factors" in the company's Annual Report on Form 10-K for the fiscal year ended June 30, 2014, which was filed with the SEC on September 26, 2014.

Financial tables follow 

APPLIED GENETIC TECHNOLOGIES CORPORATION
CONDENSED BALANCE SHEETS
(UNAUDITED)
(in thousands, except per share data)
 
  December 31,
2014
  
June 30,
2014
ASSETS    
     
Current assets:    
Cash and cash equivalents $   44,229 $    8,623
Investments  31,113  64,450
Grants receivable  971  487
Prepaid and other current assets  1,121  1,876
Total current assets  77,434  75,436
     
Investments  21,411 —
Property and equipment, net  518  402
Intangible assets, net  1,502  1,565
Other assets  7  4
Total assets $  100,872 $  77,407
     
LIABILITIES AND STOCKHOLDERS' EQUITY    
     
Current liabilities:    
Accounts payable $  517 $  949
Accrued and other liabilities  2,207  1,585
Total current liabilities  2,724  2,534
Total liabilities   2,724  2,534
     
Stockholders' equity:    
Common stock, par value $.001 per share, 150,000 shares authorized;
16,441 and 14,082 shares issued and outstanding at December 31, 2014 and June 30, 2014, respectively
 16  14
Additional paid-in capital 172,497 139,193
Accumulated deficit   (74,365)   (64,334)
Total stockholders' equity  98,148  74,873
Total liabilities and stockholders' equity $  100,872 $ 77,407
 
 
APPLIED GENETIC TECHNOLOGIES CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
(in thousands, except per share data)
 
  For the three months
ended December 31,
For the six months
ended December 31,
  2014 2013 2014 2013
         
Revenue:        
Grant revenue $  652 $    275 $  1,257 $  466
Sponsored research and other revenue —  240 100 307
Total revenue 652 515 1,357 773
         
Operating expenses:        
Research and development 3,438 2,230 7,871 3,673
General and administrative 1,916 1,190 3,597 1,971
Total operating expenses 5,354 3,420 11,468 5,644
Loss from operations  (4,702)  (2,905)  (10,111)  (4,871)
         
Other income (expense):        
Investment income 52 8 80 15
Fair value adjustments to warrant liabilities —  35 —  (105)
Fair value adjustments to Series B purchase rights —  2,127 —   (2,838)
Total other income (expense), net  52  2,170 80  (2,928)
Net loss $ (4,650) $ (735) $ (10,031) $ (7,799)
Net loss per share, basic and diluted $ (0.28) $ (6.74) $ (0.63) $ (71.55)
Weighted-average shares outstanding, basic and diluted  16,422  109 16,027  109

David Carey Lazar Partners Ltd. T: (212) 867-1768 Corporate Contact: Larry Bullock Chief Financial Officer Applied Genetic Technologies Corporation T: (386) 462-2204

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 95

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
TDH's First-Half Revenue Grew, but Margins Vanished

Updated Category News Views 106

A rental business can add tenants and still march backward, and TDH Holdings just demonstrated the ugly math. For the six months ended June 30, 2026, revenue from continuing operations rose 26.45% to $0.74 million. That is the pleasant number, and it deserves exactly one polite nod. Everything beneath it looks far less comfortable: costs climbed faster than revenue, gross...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 79

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
SOCi's MCP Push Makes Context the Product Moat Bigger

Updated Category News Views 135

Software agents without decent business context are just eager interns with access to the keyboard. SOCi’s November 19, 2026 announcement gets at that unglamorous truth: the company has made its Model Context Protocol server generally available and says its context layer now connects with more than 140 integrations. It is not a flashy new chatbot stunt. It is a bid to...

Continue Reading
CMA Wins Spotlight Greenberg Traurig’s Music Bench

Updated Category News Views 119

Four trophies on one awards night can say plenty about the machinery behind a music career, even if nobody should confuse a CMA acceptance speech with a balance-sheet event. Greenberg Traurig’s entertainment practice is celebrating client wins at the 60th annual CMA Awards, held Nov. 18, 2026: three honors tied to Miranda Lambert and one for Brooks & Dunn. For investors...

Continue Reading
AI Governance Is Becoming Enterprise Infrastructure

Updated Category News Views 8

Governance Has Finally Reached the Engine Room Enterprise AI is no longer a shiny pilot parked in some innovation lab; it is creeping into business-critical work, and that changes the argument entirely. Frost & Sullivan’s latest analysis makes a sensible point that too many executives still resist: AI governance is becoming a strategic operating capability, not merely a...

Continue Reading
Thanksgiving Kitchen Safety Is No Place for Autopilot

Updated Category News Views 126

Steam, chatter, and one forgotten burner can turn a holiday meal ugly in a hurry. The Consumer Product Safety Commission’s Nov. 19, 2026 reminder lands on a point that should not need repeating, yet plainly does: Thanksgiving kitchens demand attention, not casual optimism. This is not about ruining anybody’s celebration with a lecture. It is about recognizing that a...

Continue Reading
Sailun’s COP31 Pitch Rests on Tire Tech and Hard Proof

Updated Category News Views 113

Antalya Put Tire Chemistry on a Very Public Stage Rubber tires rarely get a starring role at a climate summit, which is exactly why Sailun Group’s appearance at COP31 deserves a closer look. From November 9 through 20 in Antalya, Türkiye, Chairwoman Yanhua Liu used the United Nations climate gathering to lay out the company’s case: better tire technology can cut...

Continue Reading
BET's HBCU Basketball Bet Is Bigger Than Six Games

Updated Category News Views 46

December television usually hands the microphone to the same old basketball machinery, which makes BET putting HBCU hoops in primetime feel overdue rather than merely promotional. Beginning December 3 at 8:00 p.m. ET, BET and Straight Shooter Media will air a six-game series built around Howard University and a rotating slate of opponents. The opener is Grambling State...

Continue Reading
YYForce Security Win Adds Recurring Singapore Revenue Base

Updated Category News Views 124

A retail-property security mandate rarely makes anyone pound the table, and frankly it should not. Still, YYForce has landed a tangible two-year contract in Singapore worth roughly S$831,120, with subsidiary Uniforce Security Services set to begin work on December 1, 2026. For NASDAQ:YFOR investors, this is the kind of small, operationally real win that deserves a sober...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Notary Journal Offers Streamlined Solutions

Updated Category News Views 108

Transforming Notary Services In the realm of notary services, efficiency and organization are paramount. An inventive spirit from Richmond has stepped forward, seeking to revolutionize the notary journal—a pivotal tool for professionals in this industry. The concept, aptly named the NOTARY JOURNAL, aims to streamline the process of recording signatures and vital...

Continue Reading
Cappfinity's Big Bet: Reshaping Leadership Impact

Updated Category News Views 20

Leadership Reimagined for a Changing World The market's no walk in the park right now, and Cappfinity’s stepping in with its new Leadership Contribution Platform to tackle the very thing that every organization’s biting nails over—leadership. We're talking about a total shift in how leadership’s gauged, understood, and developed. And yep, it’s about time someone...

Continue Reading
Spain Invests €19.6M in Quantix for Cybersecurity Hub

Updated Category News Views 239

Spain Boosts Cybersecurity Innovation with Quantix Investment The Spanish government's latest initiative aims to enhance cybersecurity and microelectronics innovation through an impressive investment of €19.6 million in Quantix. This investment is part of a broader effort to develop a cutting-edge Cybersecurity and Microelectronics Center in a strategic region....

Continue Reading
Innovative Income Strategies with New Simplify ETFs Launch

Updated Category News Views 232

Innovative Income Strategies with New Simplify ETFs Launch In a move designed to empower investors, Simplify Asset Management has introduced two innovative Exchange Traded Funds (ETFs) aimed at delivering capital-efficient exposure to gold and U.S. small-cap equities while generating consistent income. The newly launched funds are the Simplify Gold Strategy PLUS Income...

Continue Reading
California Takes Action Against Exxon Mobil for Plastic Waste

Updated Category News Views 121

California's Bold Move Against Exxon Mobil The state of California has initiated a major lawsuit against Exxon Mobil, one of the world's leading oil companies, accusing it of being complicit in the global plastic waste crisis. This legal action was announced by Attorney General Rob Bonta during an event focused on the necessity of climate action. Details of the Lawsuit...

Continue Reading